NEW YORK (360Dx) – A team led by researchers from Cleveland Clinic and protein biomarker firm Cleveland Diagnostics has presented preliminary data from a study indicating that their IsoPSA prostate cancer test could offer more accurate diagnosis than standard prostate-specific antigen (PSA) testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.